{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-109571","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-08-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.708213+00:00","generated_at":"2026-05-17T12:16:33.153286+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen receives China SAMR approval for sale of China business to AstraZeneca; closing expected in Q3 2025","bullets":["China State Administration for Market Regulation decided not to prohibit AstraZeneca's acquisition of FibroGen China.","Transaction includes all equity of FibroGen International (Hong Kong) Ltd. and roxadustat assets in China.","Closing expected in Q3 2025, subject to customary closing conditions and deliverables.","FibroGen retains roxadustat rights in US, Canada, Mexico, and other non-AstraZeneca/Astellas territories."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-109571","json":"https://secwatch.observer/filing/0000950170-25-109571.json","markdown":"https://secwatch.observer/filing/0000950170-25-109571.md","text":"https://secwatch.observer/filing/0000950170-25-109571.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025109571/0000950170-25-109571-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025109571/fgen-20250818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:16:33.153286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}